SARS-CoV Inhibitors

SARS-CoV inhibitors are a class of antiviral agents developed to combat infections caused by Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), and more broadly, its highly pathogenic relatives like SARS-CoV-2, the causative agent of COVID-19. Coronaviruses are enveloped, positive-sense single-stranded RNA viruses. Their mechanism of action involves a complex life cycle within host cells, beginning with attachment via the spike (S) protein to host cell receptors, primarily angiotensin-converting enzyme 2 (ACE2). Following entry, the viral RNA genome is released into the cytoplasm, where it is translated into large polyproteins. These polyproteins are then cleaved by viral proteases, particularly the main protease (Mpro, also known as 3CLpro) and papain-like protease (PLpro), into individual non-structural proteins (nsps). These nsps form the viral replication-transcription complex (RTC), which includes the RNA-dependent RNA polymerase (RdRp), responsible for replicating the viral genome and transcribing subgenomic RNAs. The main signaling pathways targeted by inhibitors are thus viral entry, proteolytic processing, and RNA replication/transcription. SARS-CoV and SARS-CoV-2 infections are associated with severe acute respiratory syndrome, characterized by fever, cough, dyspnea, and in severe cases, acute respiratory distress syndrome (ARDS), multi-organ failure, and death.

The initial SARS-CoV outbreak in 2002-2003 caused significant mortality, and the subsequent emergence of SARS-CoV-2 led to the devastating COVID-19 pandemic, impacting global health, economies, and societies on an unprecedented scale. The disease spectrum ranges from asymptomatic infection to critical illness, with long-term sequelae ("long COVID") also being a significant concern. The urgent need for effective therapeutics during the pandemic accelerated research into SARS-CoV-2 inhibitors. Current research progress in SARS-CoV inhibitors, particularly for SARS-CoV-2, has been rapid and extensive. Several drugs have received emergency use authorization or full approval. Remdesivir, a nucleoside analog that inhibits the viral RdRp, was one of the first approved treatments for hospitalized COVID-19 patients. Nirmatrelvir/ritonavir (Paxlovid), an oral combination therapy, targets the viral Mpro, preventing the cleavage of polyproteins essential for replication, and is approved for early treatment of mild-to-moderate COVID-19 in high-risk individuals. Molnupiravir, another oral nucleoside analog, introduces errors during viral RNA replication (lethal mutagenesis).

Monoclonal antibodies (e.g., sotrovimab, bebtelovimab) targeting the S protein were developed to block viral entry, though their efficacy has been challenged by the emergence of new viral variants. Preclinical research continues to explore a wide array of targets, including PLpro, helicase, and host factors involved in viral replication. Common classifications of SARS-CoV inhibitors include RdRp inhibitors (nucleoside analogs), protease inhibitors (Mpro inhibitors, PLpro inhibitors), and entry inhibitors (S protein-targeting antibodies, small molecules blocking ACE2 interaction or membrane fusion). Host-directed therapies, such as immunomodulators (e.g., corticosteroids, IL-6 inhibitors) and anticoagulants, are also crucial for managing severe disease but are not direct antiviral inhibitors. Research tool compounds, such as specific Mpro or RdRp inhibitors, have been instrumental in drug discovery. Challenges include the rapid evolution of the virus, leading to the emergence of drug-resistant variants and necessitating continuous development of new inhibitors. Toxicity, particularly with broad-spectrum antivirals, and drug-drug interactions (e.g., ritonavir's CYP3A inhibition) are important considerations. Combination therapy, such as nirmatrelvir/ritonavir, is a successful strategy to enhance efficacy and potentially mitigate resistance.

The development of pan-coronavirus inhibitors, effective against multiple sarbecoviruses, remains a significant goal to prepare for future pandemics, alongside ongoing efforts in vaccine development and public health measures.